Case ReportsAn Option to Consider for Alternating Hemiplegia of Childhood: AripiprazoleDundar, Nihal Olgac MD*; Cavusoglu, Dilek MD†; Kaplan, Yusuf Cem MD‡; Hasturk, Mehmet Oytun MD§ Author Information *Department of Pediatric Neurology, Faculty of Medicine, Izmir Katip Celebi University, Izmir; †Department of Pediatric Neurology, Faculty of Medicine, Afyonkocatepe University, Afyon; ‡Department of Pharmacology and Teratology Information, Research and Training Center, Faculty of Medicine, Izmir Katip Celebi University; and §Department of Child and Adolescent Psychiatry, Ataturk Training and Research Hospital, Izmir, Turkey. Address correspondence and reprint requests to Nihal Olgac Dundar, Department of Pediatric Neurology, Tepecik Research Hospital, Izmir Katip Celebi University, 1140/1 St, No. 1 Yenisehir, Konak, Izmir, Turkey; E-mail: [email protected] Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare. Clinical Neuropharmacology: 5/6 2019 - Volume 42 - Issue 3 - p 88-90 doi: 10.1097/WNF.0000000000000339 Buy Metrics Abstract Alternating hemiplegia of childhood (AHC) is an infrequent neurological disorder characterized by recurrent transient attacks of hemiplegia that last minutes to days and impress either side of the body, dystonic or tonic attacks, and nystagmus. Cognitive or neurological deficits with progressive course are another findings. Epileptic seizures may occur in some patients. We report the medical treatment in a case of AHC in a-12-year-old male patient with convulsions. The patient did not respond to available therapies for AHC, except for aripiprazole. After the initiation of aripiprazole therapy, duration and frequency of hemiplegia episodes were decreased. Also, he is currently seizure-free with topiramate treatment for 3 months. On follow-up, a compound heterozygous ATP1A3 mutation c.868C > T (p.R290C)/c.684 + 1G > A was determined. Aripiprazole may reduce the attacks of AHC, which are resistant to other available therapies. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.